ACF

ACF Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to discovering and developing novel small molecule inhibitors for the treatment of inflammation-induced cancers. Formed in 2015 as a strategic partnership between MD Anderson Cancer Center, Cayman Chemical, and Fannin Innovation Studio, the company focuses on targeting the PGE2 pathway to block cancer progression and enhance anti-tumor immune responses. By developing more specific modulators of the cyclooxygenase (COX) pathway, ACF aims to provide therapeutic benefits for patients with melanoma, colon, and pancreatic cancer while avoiding the side effects associated with traditional COX inhibitors. The company leverages the research expertise of MD Anderson and the chemical synthesis capabilities of Cayman Chemical to advance its pipeline of anti-cancer agents.